The CD55-Smad4 had a markedly higher cytopathic effect on CRC cells than CD55-EGFP and had a greater inhibitory effect on CRC cells than CD55-EGFP in vitro and in vivo (Figure 2). This evidence concerns the gene CD55 and colorectal carcinoma.